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Premature cardiovascular disease and death with a functioning graft are leading 
causes of death and graft loss, respectively, in kidney transplant recipients (KTRs). 
Vascular stiffness and calcification are markers of cardiovascular disease that are 
prevalent in KTR and associated with subclinical vitamin K deficiency. We performed 
a single- center, phase II, parallel- group, randomized, double- blind, placebo- controlled 
trial (ISRCTN22012044) to test whether vitamin K supplementation reduced vascu-
lar stiffness (MRI- based aortic distensibility) or calcification (coronary artery calcium 
score on computed tomography) in KTR over 1 year of treatment. The primary out-
come was between- group difference in vascular stiffness (ascending aortic distensibil-
ity). KTRs were recruited between September 2017 and June 2018, and randomized 
1:1 to vitamin K (menadiol diphosphate 5 mg; n = 45) or placebo (n = 45) thrice weekly. 
Baseline demographics, clinical history, and immunosuppression regimens were simi-
lar between groups. There was no impact of vitamin K on vascular stiffness (treatment 
effect −0.23 [95% CI −0.75 to 0.29] × 10−3 mmHg−1; p = .377), vascular calcification 
(treatment effect −141 [95% CI − 320 to 38] units; p = .124), nor any other outcome 
measure. In this heterogeneous cohort of prevalent KTR, vitamin K supplementation 
did not reduce vascular stiffness or calcification over 1 year. Improving vascular health 
in KTR is likely to require a multifaceted approach.
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1  |  INTRODUC TION
Cardiovascular disease is a major cause of morbidity in patients with 
chronic kidney disease (CKD) and is most pronounced in those with 
end- stage kidney disease (ESKD). The risk of cardiovascular disease 
is attenuated by kidney transplantation, but cardiovascular risk re-
mains elevated compared with the general population,1 progresses 
with declining transplant function2 and is a major cause of death 
with a functioning graft.3
In CKD, cardiovascular risk can be partly attributed to ath-
erosclerotic risk factors seen in the general population, such as 
smoking, dyslipidemia, and hypertension. However, secondary 
prevention strategies for cardiovascular disease (including anti-
platelet and statins) are inadequate to address the excess cardio-
vascular risk seen in kidney transplant recipients (KTRs).4- 8 People 
with advanced CKD including KTR exhibit markers of cardiovas-
cular aging that are more CKD- specific, and disproportionate for 
age and gender, such as vascular stiffness and calcification.9- 11 
These markers are independently and significantly associated 
with cardiovascular disease and mortality among KTRs,12- 14 and 
there are no specific treatments available to improve vascular 
stiffness and calcification.
Vascular calcification impairs the ability of a vessel to stretch 
and relax, resulting directly in vascular stiffness, increased after-
load, hypertension, and left ventricular hypertrophy.15 Vascular 
calcification in CKD results from a relative excess of calcifica-
tion promoters (e.g., CKD mineral and bone disorder, dyslipid-
emia, and diabetes) compared with inhibitors (including vitamin 
K– dependent proteins and magnesium).16 Vitamin K is an essen-
tial cofactor for posttranslational carboxylation (activation) of 
a number of calcification inhibitors, such as Matrix Gla protein, 
osteocalcin, and Gla- rich protein.17 In subclinical vitamin K defi-
ciency, these calcification inhibitors are incompletely activated, 
and vascular calcification can progress unopposed.18 Activity 
of these calcification inhibitors, and thus vitamin K status, can 
be estimated by measuring the levels of undercarboxylated en-
zyme in the blood.19,20 Of these, desphospho- undercarboxylated 
Matrix Gla Protein (dp- ucMGP) may be the most sensitive for de-
tecting changes in vitamin K status.21
Vitamin K deficiency is common among KTRs (at least in part due 
to suboptimal dietary intake22) and is associated with cardiovascular 
disease and increased mortality in this population.23 Vitamin K sup-
plementation may provide an inexpensive and low- risk treatment to 
attenuate progression of vascular stiffness and calcification in KTR 
by optimizing the function of vitamin K– dependent calcification 
inhibitors.
Trials of vitamin K to improve vascular stiffness and calcification 
show promising results in various populations.24 We designed the 
ViKTORIES trial (Vitamin K in kidney Transplant Organ Recipients: 
Investigating vEssel Stiffness) to investigate the hypothesis that vi-
tamin K supplementation improves vascular stiffness and calcifica-
tion over 1 year in prevalent KTR.
2  |  MATERIAL S AND METHODS
The full ViKTORIES methods have been published previously.25
2.1  |  Trial design and participants
This was a single- center, phase II, parallel- group, randomized, double- 
blind, placebo- controlled trial in prevalent KTR. Adult participants 
(18 years or over) who had a functioning kidney transplant for a year 
or more (eGFR >15 ml/min/1.73 m2 by CKD- EPI26) were included. 
There was no minimum threshold for vascular stiffness or calcifica-
tion. We excluded participants with the following: permanent or 
paroxysmal atrial fibrillation (known or identified at screening), war-
farin use, taking vitamin K or indication for vitamin K, allergies to 
constituent ingredients of the study interventions (gelatin, lactose, or 
cellulose), breastfeeding or of childbearing potential, known glucose- 
6- phosphate dehydrogenase deficiency, life expectancy <12 months, 
standard contraindications to magnetic resonance imaging (MRI),27 or 
inability to provide written informed consent in English.
2.2  |  Interventions
Full details of the choice and preparation of interventions have been 
detailed previously.25 In brief, participants were randomized to me-
nadiol diphosphate 5 mg or a matching placebo, administered orally 
three times per week (Monday, Wednesday, Friday) for 12 months. 
Menadiol diphosphate has not been used previously for this indi-
cation; however, it is a licensed preparation to correct vitamin K 
deficiency and has demonstrated similar biological activity to phy-
tomenadione (vitamin K1) for correction of coagulopathy associated 
with liver disease.28 This preparation was selected as it facilitated 
production of a matching placebo. Daily requirement of vitamin K 
is around 1 µg/kg.29 The dose of 5 mg thrice weekly was, therefore, 
considered adequate to ensure saturation of vitamin K stores.
2.3  |  Randomization sequence generation
A computer- generated code list was provided by Sealed Envelope 
(Sealed Envelope Ltd) in a password- protected file to the drug manu-
facturer (Tayside Pharmaceuticals) to produce identical, sequentially 
numbered bottles containing either vitamin K or placebo. The code 
list was organized in random permuted blocks to facilitate 1:1 un-
stratified allocation ratio.
2.4  |  Allocation concealment mechanism
Randomization was conducted by study investigators using a 
custom- built, password- protected, web- based system, created 
    |  3LEES Et aL.
and maintained by a third party not otherwise involved in the trial 
(Sealed Envelope Ltd).
2.5  |  Implementation
Participants were recruited (J.S.L.) from routine outpatient transplant 
clinic appointments in the west of Scotland (NHS Greater Glasgow and 
Clyde with a Patient Identification Centre in NHS Lanarkshire [Scotland, 
UK]) and enrolled into the study, including obtaining informed consent 
and randomizing according to methods detailed above.
2.6  |  Blinding
Local investigators, research nurses, pharmacy staff, and partici-
pants were blinded to treatment allocation by use of numbered 
but otherwise identical medication bottles. Investigations including 
laboratory analysis of blood and urine samples, pulse wave velocity 
measurements, and quality of life questionnaires were conducted by 
blinded study investigators or laboratory staff. After enrollment in 
the study, participants were given a five- digit study ID (two- digit site 
code “01” followed by three- digit sequential screening code).
2.7  |  Data capture
A custom- designed electronic case report form was used, designed 
(by J.S.L.) using Castor Electronic Data Capture (www.casto redc.
com; Amsterdam, the Netherlands).
2.8  |  Outcomes
The primary outcome was between- group difference measured by 
MRI- based ascending aortic distensibility at 12 months. All secondary 
outcomes were assessed as between- group differences at 12 months 
and were tested hierarchically in the following order: coronary artery 
calcification score (CACS) by non- contrast computed tomography 
(CT), carotid- femoral pulse wave velocity and augmentation index 
(SphygmoCor XCEL PWA and PWV software, AtCor Medical Pty Ltd), 
MRI measures of cardiac structure and function (descending aortic dis-
tensibility, left/right ventricular mass, function and peak systolic strain, 
T1 and T2 relaxation times), office blood pressure, electrocardiogram 
(ECG), calcium metabolism and bone turnover markers (calcium, phos-
phate, parathyroid hormone, 25- hydroxyvitamin D), transplant func-
tion, proteinuria, and quality of life (EuroQol EQ- 5D- 5L instrument30).
2.9  |  Vitamin K status
dp- ucMGP was used as a marker of vitamin K status to confirm biolog-
ical effect of supplementation. dp- ucMGP was measured in thawed 
plasma samples using an automated chemiluminescence sandwich 
immunoassay (InaKtifMGP) provided by ImmunoDiagnosticSystems 
(IDS PLC, Tyne and Wear) and processed on an IDS- iSYS instrument 
in the biochemistry laboratory at Glasgow Royal Infirmary, NHS 
Greater Glasgow and Clyde. During assay verification, there were 
concerns about linearity due to problems with variable recovery par-
ticularly at the lower end of the assay (<900 pmol/L). Reporting of 
absolute values of dp- ucMGP was possible above 900 pmol/L, but 
not below, and dp- ucMGP values <900 pmol/L were, therefore, con-
sidered to be equal to 900 pmol/L.
2.10  |  Imaging acquisition and assessment
Full details of the MRI and CT image acquisition sequences and 
analysis are available in the published protocol.25 Participants un-
derwent ECG- gated, non- contrast cardiac MRI on a Siemens Prisma 
3 T scanner (Siemens Healthineers). CACS was obtained using an 
Aquilion ONE Vision Edition CT scanner (Canon Medical Systems 
Ltd.).
Aortic volumes were obtained from MRI cine images, with si-
multaneous blood pressure measurements. Aortic distensibility 
(mmHg−1) in ascending and descending aorta was then calculated 
from the following equation31- 33:
MRI outcomes were assessed on dedicated software (CVi42, 
Circle Cardiovascular Imaging) by a single observer blinded to treat-
ment allocation (J.S.L.), with blinded re- analysis of n = 20 randomly 
selected data sets, in random order, for intra- and inter- observer 
(L.Y.Z.) variability for all primary and secondary imaging outcomes. 
CACS was calculated by the Agatston method34 using Vitrea 
Advanced Visualization software (Vital Images Inc.) by a consultant 
radiologist blinded to treatment allocation (G.H.R.), excluding seg-
ments with previous coronary artery stents in situ.
2.11  |  Analysis and statistical considerations
ViKTORIES was analyzed in line with CONSORT guidelines, and the 
analysis plan was published in advance of locking the database (Data 
S1). The primary analysis was conducted by modified intention- to- treat 
(participants were included if they completed two scans irrespective 
of whether they stayed on study medication), except changes in dp- 
ucMGP, which were studied in participants who completed the study 
per- protocol. Outcomes were assessed as between- group difference 
at 12 months by two- way analysis of covariance (ANCOVA) adjust-
ing for age, duration of ESKD, and the baseline value of the variable 
of interest. Plasma dp- ucMGP concentrations were log- transformed 
prior to analysis. Prespecified subgroup analysis was conducted in 
older (≥65 years) versus younger (<65 years) participants, testing for 
AD =
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multiplicative interaction effect between age and treatment group 
and heterogeneity of treatment effect.35 Exploratory analyses by 
ANCOVA were conducted to assess the impact of baseline dp- ucMGP 
on vascular outcomes of interest, and ANCOVA repeated as for main 
outcomes in a subgroup of participants considered to be vitamin K de-
ficient at baseline (dp- ucMGP >900 pmol/L). We conducted multiple 
imputation for missing data (using the average of five separately im-
puted data sets) for the main outcomes where the assumption of miss-
ing at random was met.36 The number and characteristics of adverse 
events (AEs) were summarized as a whole and by study arm. Results 
from the ViKTORIES trial were combined with other published reports 
in an updated meta- analysis (using a random effects model) according 
to methods described previously.24 Analyses were conducted using 
stats, subgroup, mice, and meta packages for R statistical software37 
(version 3.5.3 or higher).
2.12  |  Sample size
The sample size was calculated to detect a 1.0 × 10−3 (SD 1.3 × 10−3) 
mmHg−1 improvement in ascending aortic distensibility in the interven-
tion group relative to placebo at 12 months. This difference was shown 
to be the minimum meaningful difference associated with cardiovas-
cular outcomes in a historical cohort of hemodialysis patients from our 
own center.31 To achieve a power of 90% with alpha = 0.05 required 
37 patients per group (74 in total). We anticipated 20% dropout over 
12 months of follow- up and, therefore, recruited 90 participants.
2.13  |  Follow- up and timetable
Randomized participants completed visits at baseline and 12 months 
for all relevant clinical, biochemical, and radiological data, with moni-
toring visits at 1 and 6 months. The study duration was selected by 
extrapolating the duration from other studies where a positive re-
sult was obtained (range 1– 3 years),24 but there was an influence 
of trial cost and feasibility on the duration selected. We considered 
that if no significant impact was demonstrated on surrogate markers 
at 1 year, the influence on hard cardiovascular outcomes over the 
longer term was likely to be minimal.
2.14  |  Safety
AEs were recorded from the time a participant consented until the 
last study visit. Several events were classed as expected due to 
high levels of comorbidity in this patient cohort: death or hospitali-
zation due to new cardiovascular event, new diagnosis or treatment 
of cancer, fall, fracture, infection, exacerbation of an existing medi-
cal condition, deteriorating kidney function, high or low potassium 
F I G U R E  1  CONSORT diagram of 
included and excluded participants
Assessed for eligibility (n=192)
Excluded (n=102)
Not meeting inclusion criteria (n=36)
Declined to participate (n=66)
Other reasons (n=0)
Analysed (n=42)
Modified intention to treat analysis (n=42)
Per-protocol analysis (n=33)




Suspected adverse reaction (n=2)
Concomitant illness (n=3)
Non-adherent (n=3)
No follow-up MRI (n=2)
Claustrophobia (n=2)
Allocated to Vitamin K (n=45)
Received allocated intervention (n=45)
Did not receive allocated intervention (n=0)




No follow-up MRI (n=1)
Claustrophobia (n=1)
Allocated to Placebo (n=45)
Received allocated intervention (n=45)
Did not receive allocated intervention (n=0)
Analysed (n=41)
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levels, nausea, vomiting, constipation, diarrhea, and admission for 
elective or planned investigation or treatment. Only suspected un-
expected serious adverse reactions (SUSARs) were collected in an 
expedited manner (within 24 hours of the site becoming aware of 
the event) and reported to the sponsor via the Pharmacovigilance 
Office. Participants with unresolved AEs at the last study visit were 
followed up until resolution or 30 days (whichever was sooner).
2.15  |  Registration
ViKTORIES was prospectively registered with ISRCTN Registry on 
26/09/2017 (ISRCTN22012044).
2.16  |  Ethics
The study was conducted according to the Declaration of Helsinki 
(1964) and its revisions. The trial was approved by the West of 
Scotland Research Ethics Committee 4 (Ref: 17/WS/0101 on 
22/06/2017) and was sponsored by NHS Greater Glasgow and 
Clyde Research and Development Department (Ref: GN16RE696 
on 22/09/2017). The study followed standard operating proce-
dures of the trial Sponsor (https://www.glasg owctu.org/sops.aspx; 
NHS Greater Glasgow and Clyde, Scotland, UK as part of Glasgow 
Clinical Trials Unit). Trial progress was monitored by Sponsor rep-
resentatives from pharmacy, research, and development and by 
the Clinical Trials Manager (K.B.); routine audit was conducted 
by Sponsor in 2018. An annual report was issued to the Research 
Ethics Committee and to the funder (Kidney Research UK). The 
study followed CONSORT guidelines (http://www.conso rt- state 
ment.org).
3  |  RESULTS
3.1  |  Study participants and recruitment
Of 192 potential participants assessed for eligibility, 90 were 
recruited (September 2017 to June 2018 with follow- up to July 








Male: n (%) 32 (71.1) 31 (68.9) 63 (70.0)
Age (years) 56.3 (11.1) 58.9 (7.8) 57.6 (9.6)
Ethnicity
Caucasian: n (%) 44 (97.8) 44 (97.8) 88 (97.8)
Asian: n (%) 1 (2.2) 1 (2.2) 2 (2.2)
Deprivation: median (IQR)a 4 (2– 5) 4 (2– 5) 4 (2– 5)
Transplant age (years): 
median (IQR)
8.7 (3.5– 16.9) 6.3 (3.5– 11.7) 7.8 (3.5– 
13.9)









Diabetes mellitus: n (%) 4 (8.9) 1 (2.2) 5 (5.6)
Hypertension: n (%) 0 (0.0) 2 (4.4) 2 (2.2)
Glomerulonephritis: n (%) 11 (24.4) 12 (26.7) 23 (25.6)
Polycystic kidney 
disease: n (%)
10 (22.2) 11 (24.4) 21 (23.3)
Vascular disease: n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Other: n (%) 15 (33.3) 16 (35.6) 31 (34.4)
Not known: n (%) 5 (11.1) 3 (6.7) 8 (8.9)
Other medical history
Ischemic heart disease: 
n (%)b
17 (37.8) 12 (26.7) 29 (32.2)
Heart failure: n (%) 3 (6.7) 0 (0.0) 3 (3.3)
Transient ischemic attack 
or stroke: n (%)
2 (4.4) 1 (2.2) 3 (3.3)
Peripheral vascular 
disease: n (%)
3 (6.7) 0 (0.0) 3 (3.3)
Hypertension: n (%) 42 (93.3) 44 (97.8) 86 (95.6)
Diabetes: n (%) 13 (28.9) 7 (15.6) 20 (22.2)
Liver disease: n (%) 1 (2.2) 2 (4.4) 3 (3.3)
Anthropometric data
Systolic blood pressure 
(mmHg)
150 (19) 146 (18) 148 (19)
Diastolic blood pressure 
(mmHg)
87 (13) 84 (10) 86 (12)
Mean arterial pressure 
(mmHg)
108 (13) 105 (10) 107 (12)
Pulse pressure (mmHg) 63 (16) 62 (17) 63 (17)
Body mass index (kg/m2) 28.4 (6.2) 28.1 (6.8) 28.3 (6.5)
Smoking history
Current smoker (within 
6 months)
1 (2.2) 6 (13.3) 7 (7.8)
Previous smoker 
(>6 months)
14 (31.1) 12 (26.7) 36 (40.0)
Never smoked 30 (66.7) 27 (60.0) 57 (63.3)
Alcohol









Less than once a week 9 (20.0) 7 (15.6) 16 (17.8)
Once a week or more 17 (37.8) 18 (40.0) 35 (38.9)
Quality of life (overall 
health: %)
82.6 (18.1) 72.6 (31.5) 77.6 (26.0)
aDeprivation measured by Scottish Index of Multiple Deprivation 
quintiles (1– 5: 1 = most deprived).
bIschemic heart disease = angina, previous myocardial infarction, previous 
percutaneous coronary intervention, or coronary artery bypass grafting.
Abbreviations: IQR, interquartile range; ESKD, end- stage kidney disease.
TA B L E  1  (Continued)
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2019) and randomized to vitamin K (n = 45) or placebo (n = 45). 
Participants who had baseline and follow- up MRI for the primary 
outcome measure were included in the modified intention- to- 
treat analysis (vitamin K n = 42 and placebo n = 41); n = 79 (87.8%) 
completed the study per- protocol. Reasons for withdrawal, 
discontinuation of study intervention, or lack of availability of 
follow- up MRI data are detailed in Figure 1. Median duration of 
follow- up was similar between treatment groups: vitamin K 11.6 
(IQR 11.5– 11.7) versus placebo 11.6 (IQR 11.5– 11.7) months; 
p = .919.
3.2  |  Baseline data
Baseline data for all randomized participants are illustrated in 
Tables 1 and 2. Age, sex, ethnicity, duration of kidney transplant, 












































Steroid only: n (%) 2 (4.4) 2 (4.4) 4 (4.4)
Steroid free: n (%) 2 (4.4) 5 (11.1) 7 (7.8)
Biochemical data
Hemoglobin (g/L) 131 (19) 133 (19) 132 (19)
Platelets (×109/L) 234 (60) 220 (59) 227 (60)
Urea (mmol/L) 10.8 (5.4) 10.3 (5.6) 10.5 (5.5)
Creatinine (mg/dL) 1.6 (0.6) 1.5 (0.7) 1.6 (0.7)
Sodium (mmol/L) 139 (2) 137 (19) 138 (13)
Potassium (mmol/L) 4.5 (0.3) 4.4 (0.5) 4.5 (0.4)
Calcium (mmol/L) 2.42 (0.12) 2.42 (0.16) 2.42 (0.14)
Phosphate (mmol/L) 0.97 (0.23) 0.97 (0.24) 0.97 (0.24)
Parathyroid hormone 
(pmol/L)
17.9 (21.2) 20.1 (21.3) 19.0 (21.1)
Magnesium (mmol/L) 0.71 (0.10) 0.71 (0.08) 0.71 (0.09)
Albumin (g/L) 36 (4) 37 (3) 37 (4)








2.7 (1.1) 2.8 (1.0) 2.7 (1.0)
Triglycerides 
(mmol/L)
1.8 (0.9) 1.5 (0.6) 1.7 (0.8)
25- hydroxyvitamin D 
(nmol/L)


















Carotid- femoral PWV 
(m/s)
8.4 (2.2) 8.3 (1.7) 8.4 (1.9)
Augmentation index 
(%)
18.8 (14.4) 21.6 (10.0) 19.7 (12.4)
Vascular calcification






CACS: % for age/
gender
94 (64– 99) 88 (63– 99) 92 (66– 99)
Cardiac structure and 
function
LV mass index (g/m2) 64.0 (14.1) 62.0 (14.4) 63.0 (14.2)
LV ejection fraction 
(%)
65.6 (10.0) 69.0 (7.2) 67.3 (8.8)
LV global longitudinal 
strain (%)
−15.1 (3.3) −16.7 (3.0) −15.9 (3.2)
RV global longitudinal 
strain (%)
−19.1 (7.1) −21.2 (4.8) −20.1 (6.1)
Left atrial area (mm2) 67.2 (24.9) 70.1 (24.8) 68.6 (24.7)
Right atrial area (mm2) 67.4 (24.1) 69.3 (23.9) 68.3 (23.8)
Global myocardial T1 
time (ms)
1259 (45) 1255 (42) 1257 (43)
Global myocardial T2 
time (ms)
41 (3) 42 (2) 42 (3)
Note: Data are displayed as mean (standard deviation) or median 
(interquartile range) as appropriate. p values expressed are for Chi- square, 
Student's t test or Mann– Whitney U test as appropriate.
aeGFR measured by CKD- EPI equation.
Abbreviations: CACS, coronary artery calcium score; Dp- ucMGP, 
desphospho- undercarboxylated Matrix Gla Protein; LV, left ventricular; 
PCR, protein:creatinine ratio; PWV, pulse wave velocity; RV, right 
ventricular.
TA B L E  2  (Continued)
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and ESKD were similar across treatment groups, as were base-
line levels of vascular stiffness, calcification, and dp- ucMGP.
3.3  |  Outcomes and estimation
3.3.1  |  Primary outcome
There was no difference in ascending aortic distensibility between 
groups (adjusted treatment effect −0.23 [95% CI −0.75 to 0.29] 
×10−3 mmHg−1; p = .377: Table 3). Data for descending aortic disten-
sibility are also displayed in Table 3.
3.3.2  |  Secondary outcomes
Analyses were conducted hierarchically as described but displayed 
in full for completeness. There was no significant difference in any 
clinical, biochemical (Table 4), or imaging measure (Table 5).
3.3.3  |  Vitamin K status and biological effect
Vitamin K status was similar in treatment groups at baseline. Vitamin 
K deficiency was evident in 15 (33.3%) versus 14 (31.1%) participants 
(p = .881) in vitamin K and placebo groups respectively. In n = 72 
participants who completed the study per- protocol and had avail-
able dp- ucMGP measurements, vitamin K caused a reduction in dp- 
ucMGP (i.e., improved vitamin K availability and activity) compared 
with placebo (mean difference −186 [95% CI −294 to −78] vs. −12 
[95% CI −109 to 84] pmol/L; p = .020). There remained no significant 
effect on vascular stiffness or calcification in this group. Individual 
changes in dp- ucMGP values are illustrated in Figure 2.
3.3.4  |  Inter- and intra- observer 
consistency of agreement for magnetic resonance 
imaging outcome measures
On blinded repeat analysis of 20% of randomly selected data sets 
in random order, there was good or excellent inter- and intra- 
consistency of agreement on most outcome measures (Table S1).
3.4  |  Adverse events
AEs were common in both treatment arms, although relatively less 
common in the group treated with vitamin K (57.8% vs. 80.0%): 
Table 6). Specifically, there was a lower incidence of infections 
(15.6% vs. 40%; p = .018) and musculoskeletal AEs (8.9% vs. 31.1%; 
p = .016). The latter predominantly consisted of nonspecific joint/
muscle aches. All serious AE were characterized as expected.
There were no SUSAR during the study. One participant in the 
vitamin K arm had a suspected adverse reaction (rash), classed as 
moderate. Two patients died during the study: one had a hemor-
rhagic stroke, complicated by sepsis, a seizure, and death. A second 
patient had recurrence of known posttransplant lymphoproliferative 
disease and was admitted to hospital with neutropenic sepsis due 
to community- acquired pneumonia, multi- organ failure, and death. 










12 months 2.5 (1.5) 2.7 (1.4)
Difference from baseline −0.2 (1.2) −0.2 (1.4)




−0.1 (−0.4 to 
0.3)
.596
Adjusted treatment effecta  −0.23 (−0.75 – 0.29) .377
Adjusted treatment effecta  with
multiple imputationsb 





12 months 3.9 (1.8) 3.6 (1.3)
Difference from baseline −0.2 (1.5) −0.5 (1.5)




−0.5 (−0.9 to 
−0.1)
.385
Adjusted treatment effecta  0.23 (−0.32 to 0.78) .407
Adjusted treatment effecta  with
multiple imputationb 
−0.14 (−0.39 to 0.67) .598
Note: Data are displayed as mean (SD) or mean (95% confidence interval) as appropriate.
aANCOVA adjusted for covariates of age, duration of end- stage kidney disease, and baseline value 
of ascending aortic distensibility.
bMultiple imputation for n = 88 participants excluding two participants who died during follow- up.
TA B L E  3  Primary outcome by 
intention- to- treat analysis: aortic 
distensibility
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3.5  |  Secondary analyses
3.5.1  |  Prespecified subgroup analysis in older 
versus younger participants
Prespecified subgroup analysis was conducted in participants who 
were older (age ≥65 years; n = 20) or younger (age <65 years; n = 70) at 
randomization, based on a known positive association between vascu-
lar stiffness, calcification, and increasing age. There was no evidence 
of multiplicative interaction effect between treatment group and age 
for ascending aortic distensibility (p = .892) nor for CACS (p = .981). 
Subgroup analysis in older versus younger participants shows no het-
erogeneity of treatment effect that cannot be explained by chance 
(p = .480). Those who were older at randomization displayed more 
progression in CACS when treated with vitamin K, although there was 
a significant interaction between age, duration of ESKD, and baseline 
CACS (p = .003) in these participants, which are all likely to be predic-
tive of progressive calcification. There were no differences in any of 
the imaging outcomes by treatment group in younger participants.
3.5.2  |  Exploratory analysis: baseline vitamin K status
Baseline dp- ucMGP had no impact on any vascular outcome (aortic 
distensibility: ascending and descending, CACS, and pulse wave ve-
locity) by ANCOVA. In n = 29 participants with vitamin K deficiency 
at baseline, vitamin K treatment was associated with a reduction 
(i.e., increased stiffening) in ascending aortic distensibility (adjusted 









Systolic blood pressure (mmHg) 12 months 149 (23) 146 (16)
Difference from baseline −2 (20) 0 (17)
Adjusted treatment effecta  0 (−8 to 7) .901
Diastolic blood pressure (mmHg) 12 months 85 (12) 82 (12)
Difference from baseline −2 (10) −2 (11)
Adjusted treatment effecta  1 (−4 to 5) .750
Mean arterial pressure (mmHg) 12 months 134 (17) 131 (15)
Difference from baseline 26 (14) 26 (15)
Adjusted treatment effecta  1 (−5 to 7) .762
Pulse pressure (mmHg) 12 months 64 (21) 64 (15)
Difference from baseline 0 (15) 2 (12)
Adjusted treatment effecta  0 (−1 to 0) .521
Transplant function
eGFR (ml/min/1.73 m2) 12 months 49.4 (22.0) 52.4 (22.8)
Difference from baseline −1.6 (10.9) −0.2 (8.0)
Adjusted treatment effecta  −0.2 (−4.3 to 3.9) .937
Urinary PCR (mg/mmol) 12 months 20 (<3– 131) <3 (<3– 1121)
Difference from baseline 7 (102) −3 (88)
Adjusted treatment effecta  28 (−13 to 68) .175
Quality of life (overall health: %) 12 months 82.0 (16.2) 76.6 (16.3)
Difference from baseline −0.2 (20.0) 3.5 (30.5)
Adjusted treatment effecta  3.5 (−3.3 to 10.2) .310
Vascular stiffness
Carotid- femoral PWV (m/s) 12 months 9.4 (2.1) 9.6 (2.0)
Difference from baseline 0.8 (1.9) 1.3 (1.4)
Adjusted treatment effecta  −0.1 (−0.8 to 0.6) .746
Augmentation index (%) 12 months 19.6 (13.9) 22.1 (9.5)
Difference from baseline 0.1 (14.7) 1.6 (9.4)
Adjusted treatment effecta  0.1 (−4.8 to 4.9) .979
Abbreviations: eGFR, estimated glomerular filtration rate; PCR, protein:creatinine ratio; PWV, pulse wave velocity.
aANCOVA adjusted for age, duration of end- stage kidney disease, and baseline value of the variable under test.
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treatment effect −1.2 [95% CI −2.2 to −0.2] ×10−3 mmHg−1; p = .018). 
There was no significant treatment effect on descending aortic dis-
tensibility, CACS, or pulse wave velocity.
3.6  |  Sensitivity analysis: multiple imputation
Multiple imputation was conducted for missing outcome data for 
n = 88 participants (excluding n = 2 patients who died). The propor-
tion of data missing at random for aortic distensibility (ascending and 
descending) was 5.7%; CACS 3.4%; left ventricular mass index 6.8%; 
pulse wave velocity 5.7%; and augmentation index 3.4%. Multiple 
imputation had no meaningful impact on the results of these se-
lected endpoints (Tables 3 and 5).
3.7  |  Update of meta- analysis
Among published reports across various populations, and includ-
ing results from ViKTORIES, vitamin K supplementation does not 





N = 41 p valuea 
Vascular calcification
CACS (units) 12 months 460 (53– 1626) 412 (71– 1663)
Difference from baseline 28 (0– 65) 33 (0– 87)
Adjusted treatment effecta  −141 (−320 to 38) .120
Adjusted treatment effecta  with multiple imputationb  −155 (−330 to 20) .082
CACS: % for age/gender 12 months 96 (75– 99) 90 (63– 99)
Difference from baseline 0 (0– 0) 0 (0– 1)
Adjusted treatment effecta  2 (−3 to 7) .458
Cardiac structure and function
LV mass index (g/m2) 12 months 65.9 (16.3) 63.2 (16.8)
Difference from baseline 1.4 (10.5) 0.8 (7.6)
Adjusted treatment effecta  2.1 (−2.3 to 6.4) .348
LV ejection fraction (%) 12 months 65.6 (8.9) 67.9 (7.9)
Difference from baseline 0.4 (8.9) −1.1 (6.3)
Adjusted treatment effecta  0.0 (−3.2 to 3.1) .986
LV Global longitudinal strain (%) 12 months −15.4 (3.1) −16.3 (2.2)
Difference from baseline −0.3 (2.6) 0.3 (2.6)
Adjusted treatment effecta  −1.2 (−6.1 to 3.7) .630
RV Global longitudinal strain (%) 12 months −20.1 (4.6) −21.0 (4.8)
Difference from baseline 0.4 (5.3) −0.0 (4.9)
Adjusted treatment effecta  0.8 (−1.4 to 3.0) .482
Left atrial max area (mm2) 12 months 69.7 (24.7) 70.1 (27.1)
Difference from baseline 2.1 (19.2) 0.4 (14.3)
Adjusted treatment effecta  3.1 (−5.5 to 11.7) .473
Right atrial max area (mm2) 12 months 71.5 (23.3) 73.3 (24.5)
Difference from baseline 3.0 (22.6) 3.6 (18.5)
Adjusted treatment effecta  −1.4 (−12.0 to 9.2) .790
Global myocardial T1 time (ms) 12 months 1251 (58) 1264 (40)
Difference −10 (48) 9 (33)
Adjusted treatment effecta  −16 (−35 to 2) .084
Global myocardial T2 time (ms) 12 months 43 (3) 43 (3)
Difference from baseline 1 (3) 0 (2)
Adjusted treatment effecta  1 (0 to 1.7) .135
aANCOVA adjusted for age, duration of end- stage kidney disease, and baseline value of the variable under test.
bMultiple imputation for n = 88 participants excluding two participants who died during follow- up.
Abbreviations: CACS, coronary artery calcium score; LV, left ventricular; RV, right ventricular.
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improve vascular stiffness (mean difference −2.74 [95% CI −6.25– 
0.77]%, p = .126; Figure 3A) or vascular calcification (mean differ-
ence −4.57 [95% CI −11.05– 1.91]; p = .167; Figure 3B). Details of the 
trials included in this updated meta- analysis are available in Table S2.
4  |  DISCUSSION
The ViKTORIES trial showed no evidence that treatment with a syn-
thetic form of vitamin K improves vascular stiffness or calcification 
in a heterogeneous group of KTRs. When these results were com-
bined with other published reports in meta- analyses, there was no 
observed impact of vitamin K supplementation on vascular stiffness 
or calcification across varying populations.
In CKD, vitamin K deficiency is associated with reduced activity 
of calcification inhibitors and vascular calcification38,39 and may be 
associated with cardiovascular disease and early mortality.24 There 
are several reasons why supplementation may not have induced clin-
ical benefit in this trial.
We assumed that vitamin K as menadiol diphosphate could func-
tion as a cofactor for carboxylation of vitamin K– dependent proteins. 
Menadiol diphosphate is effective in the treatment of coagulation 
abnormalities,28 proving activity as a cofactor for carboxylation of 
vitamin K– dependent clotting factors. We tested the ability of me-
nadiol diphosphate to facilitate carboxylation of Matrix Gla protein. 
Plasma dp- ucMGP testing is not routinely available in clinical labora-
tories; commercial companies (VitaK, the Netherlands) are no longer 
offering analysis. We used the only available dp- ucMGP assay, which 
demonstrated suboptimal performance at the lower end of the scale 
in our local laboratory, and we were unable to report accurate nu-
merical values below 900 pmol/L. Griffin et al. suggested reference 
values for healthy Caucasian individuals from <300 to 532 pmol/
L40 (although no assay validation was offered for values below 
900 pmol/L). We, therefore, assumed that those with dp- ucMGP 
>900 pmol/L were “deficient” and those ≤900 pmol/L “sufficient” 
(or mildly deficient). Only 29 included participants had dp- ucMGP 
>900 pmol/L, and it is possible that a substantial proportion of par-
ticipants were not vitamin K deficient at baseline. However, there 
was a clear improvement in the absolute values of dp- ucMGP in 
those who were adherent with study medication, confirming biolog-
ical activity of menadiol diphosphate. Our results are consistent with 
other studies in CKD using different preparations of vitamin K; thus, 
it is less likely that the null result was due to the choice of prepara-
tion alone. It was not possible to confirm vitamin K status in advance 
of inclusion due to the lack of a reliable biomarker. Consideration 
could be given to testing the utility of vitamin K supplementation 
F I G U R E  2  Individual change in log 
dp- ucMGP (pmol/L) by treatment group 
from baseline to 12 months for n = 72 
participants who completed the study 
per- protocol with quantifiable dp- ucMGP 
at baseline and 12 months. Values 
<900 pmol/L could not be measured 
reliably and were considered to be equal 
to 900 pmol/L. Data have been log- 
transformed for ease of viewing values at 
the lower end of the scale
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(either alone or in combination) in patients with confirmed vitamin 
K deficiency.
We used vascular stiffness (MR- based aortic distensibility) as the 
primary endpoint. Aortic distensibility is an accurate and highly repro-
ducible measure of central vascular stiffness, that is strongly and in-
versely associated with cardiovascular risk.31 Aortic distensibility has 
been shown to be modifiable in response to therapeutic interventions 
to reduce cardiovascular risk in CKD.41 Vascular stiffness is modifiable 
over time, such as after kidney transplantation in patients with ESKD,42 
and after vitamin K supplementation in some,43,44 but not all,24 trials. 
We detected no signal that vitamin K altered vascular stiffness; it is 
unlikely that the choice of endpoint explained the null result.
Vascular stiffness and calcification develop alongside exposure 
to multiple risk factors and an imbalance of calcification promoters 
and inhibitors.16 CKD- specific risk factors— like CKD mineral and 
bone disorder— begin early in the disease process, and the effects 
persist after correction of kidney function with transplantation. 
Vitamin K is primarily obtained from green vegetables, so vitamin 
K deficiency may serve as a marker of prolonged exposure to un-
healthy diet and/or lifestyle. Vitamin K supplementation alone may 
be inadequate to reverse established effects of a lifetime of accu-
mulated vascular damage. An earlier, multifaceted, preventative ap-
proach may have greater success.
In this trial, there was a lower rate of infections and joint/muscle 
pain in the vitamin K group. Vitamin K– dependent proteins (including 
osteocalcin, Matrix Gla Protein, and Gla- rich protein) play an import-
ant role in bone mineralization and mass,45 and it is conceivable that 
this was a genuine effect of vitamin K supplementation. However, this 
outcome was not prespecified. Existing trial evidence is insufficient to 
support a role for vitamin K supplementation in improving musculo-
skeletal health including bone mineral density or fracture risk.46
This study has several limitations. First, due to the constraints 
on testing of vitamin K status detailed above, it was not possible 
to identify those with confirmed or severe vitamin K deficiency 
in advance of running the trial. It is possible that vitamin K sup-
plementation may improve vascular health in cohorts with clear 
evidence of vitamin K deficiency. Second, ViKTORIES participants 
were a heterogeneous group with heavy baseline calcification, 
which may have limited the ability of vitamin K to exert any bene-
ficial effect. Third, this population of KTRs has a lower burden of 
vascular disease and diabetes than the prevalent kidney transplant 
population in the United Kingdom and may not be representative 
of the population as a whole. Fourth, there was a slight male and 
heavy Caucasian preponderance among ViKTORIES participants, 
and the results may not be generalizable to other groups. Fifth, we 
tested vitamin K supplementation over only 1 year. It is possible 
that longer treatment is required to see a difference, particularly 
if used to reduce progression of vascular stiffness, rather than in-
duce regression of existing disease. However, our impression is 
that if there is no impact on surrogate markers of vascular health 
over 1 year, long- term impact on hard cardiovascular outcomes is 
likely to be minimal.
In conclusion, we did not find any sign that vitamin K supplemen-
tation regressed or reduced progression of vascular stiffness and 
calcification in this heterogeneous cohort of prevalent KTRs over 
1 year. These results are in keeping with meta- analyses containing 
data from other published reports. Vascular stiffness and calcifi-
cation have complex, multifactorial etiology, develop and progress 
over many years, and are unlikely to be improved substantially by 
replacement of a single dietary component on a population basis.
TA B L E  6  Adverse events by treatment arm
System organ class







Any event 26 (57.8) 36 (80.0) 62 (68.9)
Commenced dialysis 0 (0.0) 0 (0.0) 0 (0.0)
Death 0 (0.0) 2 (4.4) 2 (2.2)
Blood and lymphatic 1 (2.2) 3 (6.7) 4 (4.4)
Cardiac 3 (6.7) 0 (0.0) 3 (3.3)
Congenital and 
genetic
0 (0.0) 0 (0.0) 0 (0.0)
Ear and labyrinth 1 (2.2) 2 (4.4) 3 (3.3)
Endocrine 0 (0.0) 1 (2.2) 1 (1.1)
Eye 1 (2.2) 0 (0.0) 1 (1.1)
Gastrointestinal 7 (15.6) 8 (17.8) 15 (16.7)
General 1 (2.2) 1 (2.2) 2 (2.2)
Hepatobiliary 0 (0.0) 2 (4.4) 2 (2.2)
Immune system 0 (0.0) 0 (0.0) 0 (0.0)
Infections and 
infestations




1 (2.2) 1 (2.2) 2 (2.2)
Investigations 0 (0.0) 0 (0.0) 0 (0.0)
Metabolism and 
nutrition
1 (2.2) 0 (0.0) 1 (1.1)
Musculoskeletal 4 (8.9) 14 (31.1) 18 (20.0)
Neoplasms 1 (2.2) 0 (0.0) 1 (1.1)
Nervous system 2 (4.4) 3 (6.7) 5 (5.6)
Psychiatric 0 (0.0) 0 (0.0) 0 (0.0)
Renal and urinary 3 (6.7) 9 (20.0) 12 (13.3)
Reproductive and 
breast
2 (4.4) 0 (0.0) 2 (2.2)
Respiratory 2 (4.4) 2 (4.4) 4 (4.4)
Skin 1 (2.2) 5 (11.1) 6 (6.7)
Surgical/medical 
procedure
2 (4.4) 3 (6.7) 5 (5.6)
Vascular 1 (2.2) 0 (0.0) 1 (1.1)
Note. Number of participants with adverse events by MedDRA System 
Order Class (SOC), number of deaths and participants who commenced 
renal replacement therapy. All participants who received at least one 
dose of study medication were included in safety analyses. All serious 
adverse events were characterized as expected according to the study 
protocol.
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